% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wirthschaft:143640,
author = {P. Wirthschaft$^*$ and J. Bode$^*$ and H. Soni$^*$ and F.
Dietrich$^*$ and T. Krüwel$^*$ and B. Fischer$^*$ and C. B.
Knobbe-Thomsen and G. Rossetti and A. Hentschel and N.
Mack$^*$ and K. Schönig and M. O. Breckwoldt$^*$ and A.
Schmandke and S. Pusch$^*$ and J. Medenbach and M. Bendszus
and M. E. Schwab and A. von Deimling$^*$ and M. Kool$^*$ and
C. Herold-Mende and G. Reifenberger$^*$ and R. Ahrends and
B. Tews$^*$},
title = {{R}ho{A} regulates translation of the {N}ogo-{A} decoy
{SPARC} in white matter-invading glioblastomas.},
journal = {Acta neuropathologica},
volume = {138},
number = {2},
issn = {1432-0533},
address = {Heidelberg},
publisher = {Springer},
reportid = {DKFZ-2019-01217},
pages = {275-293},
year = {2019},
abstract = {Glioblastomas strongly invade the brain by infiltrating
into the white matter along myelinated nerve fiber tracts
even though the myelin protein Nogo-A prevents cell
migration by activating inhibitory RhoA signaling. The
mechanisms behind this long-known phenomenon remained
elusive so far, precluding a targeted therapeutic
intervention. This study demonstrates that the prevalent
activation of AKT in gliomas increases the ER
protein-folding capacity and enables tumor cells to utilize
a side effect of RhoA activation: the perturbation of the
IRE1α-mediated decay of SPARC mRNA. Once translation is
initiated, glioblastoma cells rapidly secrete SPARC to block
Nogo-A from inhibiting migration via RhoA. By advanced
ultramicroscopy for studying single-cell invasion in whole,
undissected mouse brains, we show that gliomas require SPARC
for invading into white matter structures. SPARC depletion
reduces tumor dissemination that significantly prolongs
survival and improves response to cytostatic therapy. Our
finding of a novel RhoA-IRE1 axis provides a druggable
target for interfering with SPARC production and underscores
its therapeutic value.},
cin = {V077 / B062 / D170 / B300 / L401 / L101},
ddc = {610},
cid = {I:(DE-He78)V077-20160331 / I:(DE-He78)B062-20160331 /
I:(DE-He78)D170-20160331 / I:(DE-He78)B300-20160331 /
I:(DE-He78)L401-20160331 / I:(DE-He78)L101-20160331},
pnm = {319H - Addenda (POF3-319H)},
pid = {G:(DE-HGF)POF3-319H},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31062076},
doi = {10.1007/s00401-019-02021-z},
url = {https://inrepo02.dkfz.de/record/143640},
}